로딩 중…
지수 로딩 중…
Novavax, Inc.
NVAX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$10.00+6.95%
2026-09-17
Financials
Valuation Metrics
Novavax, Inc.'s Market Cap is $1.64B. At end of 2025 it was $1.09B. Ranked #2168 of 3,121 in US market (top 69%), #853 of 1,463 on NASDAQ (top 58%), #156 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.64B | US#2,168/3,121 Sec#156/266 |
| Revenue | $414M | US#2,346/3,121 Sec#84/266 |
| Net Income | $-248M | US—/3,121 Sec—/266 |
| Total Assets | $956M | US#2,503/3,121 Sec#106/266 |
| Net Assets | $-191M | US#2,986/3,121 Sec#258/266 |
| Value | ||
| P/S | 3.97x | US#2,077/3,121 Sec#61/266 |
| FCF Yield | -2.65% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -25.92% | US#2,860/3,121 Sec#146/266 |
| Op. Margin | -54.94% | US#2,689/3,121 Sec#111/266 |
| Revenue Growth | -61.64% | US#2,751/3,121 Sec#167/266 |
| Earnings Growth | -158.59% | US#1,938/3,121 Sec#60/266 |
| Financial Health | ||
| Total Debt | $296M | US#2,107/3,121 Sec#79/266 |
| FCF | $-44M | US#2,510/3,121 Sec#110/266 |
| Cash | $191M | US#1,770/3,121 Sec#113/266 |
| Current Ratio | 2.33x | US#1,068/3,121 Sec#210/266 |
| Performance | ||
| 1Y Return | 19.19% | US#1,183/3,121 Sec#158/266 |
| 1M Return | 26.10% | US#53/3,121 Sec#11/266 |
| From 52W High | -16.46% | US#1,246/3,121 Sec#84/266 |
| 1Y MDD | -34.87% | US#1,729/3,121 Sec#115/266 |
| Trading | ||
| Volume | 8,636,965 shares | US#173/3,121 Sec#10/266 |
| Trading Value | $86M | US#915/3,121 Sec#63/266 |
| Per Share | ||
| EPS | $-1.51 | US—/3,121 Sec—/266 |
| BPS | $-1.16 | US—/3,121 Sec—/266 |